ProQR Therapeutics N.V. diskutieren
ProQR Therapeutics N.V.
WKN: A12B97 / Symbol: PRQR / Name: ProQR / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
?
0,11 %
ProQR Therapeutics (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (NASDAQ: PRQR) had its price target lowered by analysts at Raymond James from $5.00 to $4.00. They now have an "outperform" rating on the stock.
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (NASDAQ: PRQR) was upgraded by analysts at Chardan Capital from a "neutral" rating to a "buy" rating. They now have a $2.00 price target on the stock.
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (NASDAQ: PRQR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (NASDAQ: PRQR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (NASDAQ: PRQR) had its price target raised by analysts at Citigroup Inc. from $1.80 to $2.00. They now have a "buy" rating on the stock.
Ratings data for PRQR provided by MarketBeat
Der Beitrag wird untersucht
ProQR Therapeutics (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $2.50 price target on the stock.
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (NASDAQ: PRQR) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (NASDAQ: PRQR) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (NASDAQ: PRQR) was upgraded by analysts at Raymond James from an "outperform" rating to a "strong-buy" rating. They now have a $14.00 price target on the stock, up previously from $6.00.
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (NASDAQ: PRQR) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (NASDAQ: PRQR) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $15.00 price target on the stock.
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (NASDAQ: PRQR) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating. They now have a $4.00 price target on the stock.
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (NASDAQ: PRQR) had its price target raised by analysts at HC Wainwright from $10.00 to $12.00. They now have a "buy" rating on the stock.
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (NASDAQ: PRQR) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $8.00 price target on the stock.
Ratings data for PRQR provided by MarketBeat
Neueste Beiträge
Stifel_Nicolaus in Camtek Ltd. diskutieren